Samsung Epis Launches Phase 1 Global Clinical Trial Of 'Kitruda'
Samsung Epis Launches Phase 1 Global Clinical Trial Of 'Kitruda'
  • Cho Eun, Reporter
  • 승인 2024.02.21 22:37
  • 수정 2024.02.21 22:37
  • 댓글 0
이 기사를 공유합니다

Samsung Bioepis (Samsung Epis) announced on the 21st that it has launched the first phase of global clinical trials for its 11th biosimilar pipeline 'SB27 (Kitruda).

According to Samsung Epis, it has recruited 135 non-small cell lung cancer test subjects who voluntarily participated in four countries, including Korea, and started phase 1 clinical trials to compare SB27 with the pharmacokinetics, efficacy, and safety of the original drug.

KEYTRUDA is an immuno-oncology drug used for melanoma, non-small cell lung cancer, and head and neck cancer sold by the US multinational pharmaceutical company MSD.

Annual global sales reached approximately 26.3 trillion won in 2022.

Hong Il-sun, managing director of Samsung Epis, said, "Based on the global clinical operation know-how accumulated so far, we will do our best to complete clinical trials in a timely manner," adding, "Through this, we will try to provide patients with various treatment options as soon as possible."

Meanwhile, Samsung Epis will have a total of 11 biosimilar products and pipelines with SB27's entry into phase 1 clinical trials, including seven products sold in global markets such as Europe and three clinical completion pipelines.

[WIKI KOREA=Cho Eun, Reporter]

choeun@wikileaks-kr.org


  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트